Ventyx Biosciences, Inc. Stock Price, News & Analysis

Ventyx Biosciences (Nasdaq: VTYX) said company executives will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025 from 4:00–4:25 PM ET. A live webcast will be available on the company's Investors and News webpage and a replay will be posted for 30 days after the event.

Ventyx Biosciences (Nasdaq: VTYX) said company executives will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 from 11:00–11:25 AM GMT.

A live webcast will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com, and a replay will be posted on the same site for 30 days after the event.

Ventyx Biosciences (Nasdaq: VTYX) reported Q3 2025 results and pipeline progress on Nov 6, 2025. Key clinical readouts included positive Phase 2 data for the CNS‑penetrant NLRP3 inhibitor VTX3232 (hsCRP ~80% reduction; IL‑6, Lp(a), fibrinogen, ESR reductions; CSF and plasma exposures ≥3× IC90) and positive Phase 2a biomarker data in early Parkinson’s disease with biomarker and symptom improvements. Topline results for VTX2735 in recurrent pericarditis are expected Q4 2025. Cash, cash equivalents and marketable securities were $192.6M as of Sept 30, 2025, expected to fund operations into at least H2 2026.

Ventyx (Nasdaq: VTYX) reported positive Phase 2 topline results for oral once-daily VTX3232 in 175 participants with obesity and cardiovascular risk factors on Oct 22, 2025. The 12-week trial met its secondary inflammatory endpoint: VTX3232 reduced hsCRP by 78% (MAS) and 64% (FAS) versus a 3% increase with placebo (p<0.0001).

Other key findings: 69% of participants reached hsCRP <2 mg/L (MAS); median IL-6 fell to 1.60 ng/L (≤1.65 ng/L threshold); significant reductions in Lp(a), fibrinogen, ESR, and liver inflammation; safety profile comparable to placebo.

Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in three upcoming investor conferences in September 2025.

The company will present at the 2025 Wells Fargo Healthcare Conference in Boston on September 5, the Morgan Stanley 23rd Annual Global Healthcare Conference, and the H.C. Wainwright 27th Annual Global Investment Conference, both in New York on September 8. A webcast of the Wells Fargo presentation will be available on the company's website for 90 days after the event.

Ventyx Biosciences (NASDAQ:VTYX) reported Q2 2025 financial results and pipeline updates, highlighting positive developments across its drug portfolio. The company reported a strong cash position of $209.0 million, expected to fund operations into H2 2026.

Key highlights include positive Phase 2a biomarker data for VTX3232 in Parkinson's disease, demonstrating safety, high drug exposure, and potent NLRP3 biomarker suppression. Two Phase 2 studies are expected to yield results in Q4 2025: VTX2735 for recurrent pericarditis and VTX3232 for obesity with cardiometabolic risk factors.

The company's Q2 2025 financials showed reduced losses, with net loss decreasing to $27.0 million from $32.0 million year-over-year. R&D expenses decreased to $22.3 million from $27.8 million in Q2 2024.

Ventyx Biosciences (VTYX) announced positive top-line results from its Phase 2a study of VTX3232, a novel CNS-penetrant NLRP3 inhibitor, in early-stage Parkinson's disease patients. The trial met its primary objective, demonstrating safety and tolerability with no drug-related adverse events. The 28-day study of 40mg daily oral dose in 10 patients showed significant pharmacokinetic and pharmacodynamic success, with drug levels maintaining above IC90 for 24 hours. VTX3232 demonstrated clear target engagement by reducing NLRP3-related biomarkers in both plasma and CSF. Notably, patients showed statistically significant improvements in motor and non-motor symptoms measured by MDS-UPDRS Parts I, II, and III. The company plans to advance to a placebo-controlled Phase 2 trial in Parkinson's disease and potentially expand into Alzheimer's disease treatment.

Ventyx Biosciences (NASDAQ: VTYX), a clinical-stage biopharmaceutical company developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. Company executives will engage in a fireside chat on Thursday, June 5, 2025, from 12:50-1:20 PM ET in New York. The presentation will be accessible via webcast on the company's website at www.ventyxbio.com, with a replay available for 90 days following the event.

Ventyx Biosciences (VTYX) reported Q1 2025 financial results and pipeline updates. The company maintains a strong cash position of $228.8M, expected to fund operations into H2 2026. Key highlights include anticipated topline data from multiple Phase 2 studies in 2025: VTX3232 for early Parkinson's disease (Q2), VTX2735 for recurrent pericarditis (H2), and VTX3232 for obesity and cardiometabolic factors (H2). The company reported reduced losses with net loss of $27.4M in Q1 2025, down from $38.6M in Q1 2024. R&D expenses decreased to $22.9M from $33.7M year-over-year. Ventyx has positioned itself as a leader in NLRP3 inhibitors development, with two novel compounds (VTX3232 and VTX2735) advancing through clinical trials for neurodegenerative, cardiovascular, and metabolic conditions.